Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study

The pharmacokinetics (PK) and safety of single-dose alpelisib (300 mg) were assessed in participants with moderate to severe hepatic impairment (n = 6 each) compared with their matching healthy controls (n = 11). Blood samples were collected upto 144 hours post-dose and evaluated by liquid chromatog...

Descripción completa

Detalles Bibliográficos
Autores principales: Marbury, Thomas, El-Hashimy, Mona, Blumenstein, Lars, Letellier, Franck, Sengupta, Tirtha, Lorenzo, Sebastien, Preston, Richard Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266244/
https://www.ncbi.nlm.nih.gov/pubmed/37325049
http://dx.doi.org/10.7150/jca.82736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266244/
https://www.ncbi.nlm.nih.gov/pubmed/37325049
http://dx.doi.org/10.7150/jca.82736

Ejemplares similares